BUSINESS

• BMS, Pfizer to Codevelop Factor Xa Antidote in Japan
  February 5, 2016

• Ayumi Poised to In-License Several RA Biosimilars, Eyes 50 Billion Yen Sales by 2020
  February 5, 2016

• Takeda to Spin Off Consumer Healthcare Unit, New Firm to Go Live in April 2017
  February 4, 2016

• Kyorin Ends Development of COPD Combo Drug, Returns Rights to AZ
  February 4, 2016

• Mitsubishi Tanabe to Shed 10-Plus % of Japan Workforce
  February 4, 2016

• Sumitomo Dainippon Looks to Tap New Drugs to Counter US Latuda LOE
  February 4, 2016

• Sovaldi, Harvoni Haul in Nearly US$1.9 Billion in Japan: Gilead
  February 4, 2016

• Sakigake: Now and Future (1) - Topical Sirolimus on Track for Application in 2018 for 1st-in-World Indication
  February 4, 2016

• Belsomra Most Promoted Drug for GPs for 6 Straight Month: Anterio
  February 3, 2016

• Seikagaku, Kaken Call Off Artz Development for Expanded Indication
  February 3, 2016

• Sakigake-Designated NS-065 Now in PI/II: Nippon Shinyaku
  February 3, 2016

• Eisai’s Next Mid-Term Biz Plan Will Show New Twist to Generic Operations: Exec
  February 3, 2016

• J-TEC Files Skin-Derived Cell Sheet JACE for Giant Pigmented Nevus
  February 2, 2016

• Pola Pharma to Take Over GSK’s Marketing Authorization for Acne Drug Duac
  February 2, 2016

• Eisai Gets Japan, Asia Rights to HDAC Inhibitor
  February 2, 2016

• Kyowa Kirin to Boost Overseas Biz in Next 5 Years, Japan Market Unpredictable: President
  February 2, 2016

• Astellas, Tohoku Univ. Spinoff Link Up on Gene Therapy for Retinitis Pigmentosa
  February 2, 2016

• Sanofi Files Japan NDA for Plerixafor in Response to Govt Request
  February 2, 2016

• Retooling Generic Business - 3: Eisai “Carefully Considering” Future Course; “Not a Core Field,” Mitsubishi Tanabe Says
  February 2, 2016

• Daiichi Sankyo to Continue Negotiations with FDA on Edoxaban Restriction: CEO
  February 1, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 470
• 471
• 472
• 473
• 474
• 475
• 476
• 477
• 478
• …
• Next ›
• 最終 »